Fig. 7From: Nanomedicine for increasing the oral bioavailability of cancer treatmentsEffects of varying amounts of the cross-linker glutaraldehyde in preventing trypsin degradation of albumin nanoparticles. The figure was reprinted from Langer, K., Anhorn, M.G., Steinhauser, I., Dreis, S., Celeb, D., Schrickel, N., Faust, S., Vogel, V. 2008. Human serum albumin (HSA) nanoparticles: Reproducibility of preparation process and kinetics of enzymatic degradation. Int J Pharm 347(102):109–117. ElsevierBack to article page